Novo nordisk a/s: once-weekly and once-monthly mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia a in the frontier 2 trial

BagsvÆrd, denmark, 13 may 2024 – novo nordisk today announced the headline results from the frontier 2 trial, a pivotal phase 3a, 26-week open-label, randomised, controlled, multi-arm trial in 254 people. the trial investigated the efficacy and safety of once-weekly and once-monthly subcutaneous mim8 versus no prophylaxis and versus prior coagulation factor prophylaxis treatment in people aged 12 years or older with haemophilia a with or without inhibitors.
NVO Ratings Summary
NVO Quant Ranking